Eculizumab in the treatment of systemic lupus erythematosus complicated by thrombotic microangiopathy: a case report

Heng LIU, Pan-Li LIAO, Xiao-Wen WANG

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (9) : 1134-1139.

PDF(1052 KB)
HTML
PDF(1052 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (9) : 1134-1139. DOI: 10.7499/j.issn.1008-8830.2502059
CASE REPORT

Eculizumab in the treatment of systemic lupus erythematosus complicated by thrombotic microangiopathy: a case report

Author information +
History +

Abstract

The patient was a girl aged 10 years and 10 months, with weakness, pale complexion, and rash as the initial presentation. She had the manifestations of anemia, thrombocytopenia, hematuria-proteinuria with renal insufficiency, hypocomplementemia, polyserositis, and positive anti-nuclear antibody and anti-dsDNA antibody. The girl was initially diagnosed with systemic lupus erythematosus and lupus nephritis. She demonstrated a suboptimal response to methylprednisolone pulse therapy, intravenous immunoglobulin administration, and therapeutic plasma exchange. She had persistent anemia, thrombocytopenia, abnormal renal function, elevated lactate dehydrogenase, decreased complement factors H and I, increased antibodies to C3 converting enzyme, and normal ADAMTS13 activity. She was diagnosed with complement-mediated hemolytic thrombotic microangiopathy secondary to systemic lupus erythematosus. The patient's condition improved after treatment with two doses of eculizumab (600 mg per dose). Patients with systemic lupus erythematosus complicated by thrombotic microangiopathy often have a severe disease course and poor prognosis; therefore, early recognition and aggressive intervention are crucial for improving outcomes.

Key words

Systemic lupus erythematosus / Thrombotic microangiopathy / Eculizumab / Child

Cite this article

Download Citations
Heng LIU , Pan-Li LIAO , Xiao-Wen WANG. Eculizumab in the treatment of systemic lupus erythematosus complicated by thrombotic microangiopathy: a case report[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(9): 1134-1139 https://doi.org/10.7499/j.issn.1008-8830.2502059

References

[1]
沈南, 赵毅, 段利华, 等. 系统性红斑狼疮诊疗规范[J]. 中华内科杂志, 2023, 62(7): 775-784. DOI: 10.3760/cma.j.cn112138-20221027-00793 .
[2]
George JN, Nester CM. Syndromes of thrombotic microangiopathy[J]. N Engl J Med, 2014, 371(7): 654-666. DOI: 10.1056/NEJMra1312353 .
[3]
李晓洁, 魏雅琴, 高春林, 等. 系统性红斑狼疮合并血栓性微血管病的病因及治疗[J]. 中华儿科杂志, 2023, 61(8): 753-756. DOI: 10.3760/cma.j.cn112140-20221231-01078 .
[4]
Sun F, Wang X, Wu W, et al. TMA secondary to SLE: rituximab improves overall but not renal survival[J]. Clin Rheumatol, 2018, 37(1): 213-218. DOI: 10.1007/s10067-017-3793-4 .
[5]
Kwok SK, Ju JH, Cho CS, et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study[J]. Lupus, 2009, 18(1): 16-21. DOI: 10.1177/0961203308094360 .
[6]
张丹, 赖建铭, 李明, 等. 儿童系统性红斑狼疮合并血栓性微血管病临床特点及诱导缓解治疗疗效[J]. 中国新药与临床杂志, 2024, 43(2): 103-106. DOI: 10.14109/j.cnki.xyylc.2024.02.04 .
[7]
Hamasaki K, Mimura T, Kanda H, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review[J]. Clin Rheumatol, 2003, 22(4/5): 355-358. DOI: 10.1007/s10067-003-0742-1 .
[8]
中国罕见病联盟儿童非典型溶血尿毒综合征专业委员会, 国家儿童医学中心(首都医科大学附属北京儿童医院), 《中华实用儿科临床杂志》编辑委员会. 中国儿童非典型溶血尿毒综合征诊治专家共识(2023版)[J]. 中华实用儿科临床杂志, 2023, 38(6): 401-412. DOI: 10.3760/cma.j.cn101070-20230328-00257 .
[9]
Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies[J]. J Thromb Haemost, 2017, 15(2): 312-322. DOI: 10.1111/jth.13571 .
[10]
Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children[J]. Pediatr Nephrol, 2016, 31(1): 15-39. DOI: 10.1007/s00467-015-3076-8 .
[11]
陈志威, 叶霜. 系统性红斑狼疮合并血栓性微血管病[J]. 中国实用内科杂志, 2015, 35(10): 825-827. DOI: 10.7504/nk2015090106 .
[12]
Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies[J]. Br J Haematol, 2012, 158(3): 323-335. DOI: 10.1111/j.1365-2141.2012.09167.x .
[13]
李嘉欣, 张卓莉. 系统性红斑狼疮合并血栓性微血管病的诊治及预后[J]. 中华风湿病学杂志, 2018, 22(9): 642-645. DOI: 10.3760/cma.j.issn.1007-7480.2018.09.015 .
[14]
殷蕾, 茅幼英, 周征宇, 等. 儿童系统性红斑狼疮并发血栓性微血管病的临床特点和早期识别[J]. 中国小儿急救医学, 2021, 28(10): 868-873. DOI: 10.3760/cma.j.issn.1673-4912.2021.10.006 .
[15]
Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype[J]. Clin J Am Soc Nephrol, 2010, 5(10): 1844-1859. PMCID: PMC2974386. DOI: 10.2215/CJN.02210310 .
[16]
Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies[J]. Nat Rev Nephrol, 2012, 8(11): 643-657. DOI: 10.1038/nrneph.2012.214 .
[17]
章玲霞, 王晶晶, 金艳艳, 等. 伊库珠单抗治疗儿童系统性红斑狼疮合并血栓性微血管病的2例经验分享及文献复习[J]. 中华肾脏病杂志, 2023, 39(12): 942-946. DOI: 10.3760/cma.j.cn441217-20230504-00502 .
[18]
Aigner C, Gaggl M, Stemer G, et al. Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort[J]. J Nephrol, 2022, 35(2): 451-461. PMCID: PMC8927043. DOI: 10.1007/s40620-021-00981-8 .
[19]
Wright RD, Bannerman F, Beresford MW, et al. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy[J]. BMC Nephrol, 2020, 21(1): 245. PMCID: PMC7329551. DOI: 10.1186/s12882-020-01888-5 .
[20]
Bermea RS, Sharma N, Cohen K, et al. Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus[J]. J Clin Rheumatol, 2016, 22(6): 320-323. DOI: 10.1097/RHU.0000000000000423 .
[21]
El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab[J]. Am J Kidney Dis, 2015, 65(1): 127-130. DOI: 10.1053/j.ajkd.2014.07.031 .
[22]
Stiles KP, Yuan CM, Chung EM, et al. Renal biopsy in high-risk patients with medical diseases of the kidney[J]. Am J Kidney Dis, 2000, 36(2): 419-433. DOI: 10.1053/ajkd.2000.8998 .
[23]
Mustafa KN, Aladily TN, Shomaf MS, et al. Renal biopsy findings in lupus nephritis[J]. Saudi J Kidney Dis Transpl, 2011, 22(4): 815-817.
[24]
Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway[J]. Front Immunol, 2016, 7: 55. PMCID: PMC4764694. DOI: 10.3389/fimmu.2016.00055 .
[25]
Belot A, Cimaz R. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis[J]. Pediatr Rheumatol Online J, 2012, 10(1): 21. PMCID: PMC3489560. DOI: 10.1186/1546-0096-10-21 .

Footnotes

所有作者声明无利益冲突。

PDF(1052 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/